Is Boston Scientific Stock Underperforming the Nasdaq?

Core Insights - Boston Scientific Corporation (BSX) is a leading player in the medical devices industry with a market cap of $149.7 billion, focusing on various interventional medical specialties globally [1][2] Company Overview - BSX develops, manufactures, and markets medical devices for interventional cardiology, cardiac rhythm management, peripheral interventions, electrophysiology, neurovascular intervention, and endoscopy [1] - The company is categorized as a large-cap stock, emphasizing its size and influence in the medical devices sector [2] - Key strengths of BSX include a trusted brand, innovation driven by R&D, a diversified product portfolio, global reach, and strategic acquisitions [2] Stock Performance - BSX shares have experienced a decline of 7.8% from their 52-week high of $109.50, reached on September 9 [3] - Over the past three months, BSX stock has decreased by 5.1%, underperforming the Nasdaq Composite, which gained 7.8% during the same period [3] - Year-to-date, BSX shares have risen by 13%, and over the past 52 weeks, they have climbed 11.9%, but still lag behind the Nasdaq's YTD gains of 20.2% and 21.1% over the last year [4] Recent Financial Results - On October 22, BSX reported Q3 results, with an adjusted EPS of $0.75, exceeding Wall Street's expectation of $0.71 [5] - The company's revenue for the quarter was $5.1 billion, surpassing the forecast of $5 billion [5] - BSX anticipates full-year adjusted EPS in the range of $3.02 to $3.04 [5] Competitive Landscape - In comparison, Stryker Corporation (SYK) has shown weaker stock performance, with a YTD gain of only 3.4% and a 4.5% decline over the past 52 weeks [5]